The estimated Net Worth of Brooke Story is at least $91.2 ezer dollars as of 15 June 2024. Brooke Story owns over 2,680 units of Sigilon Therapeutics stock worth over $91,228 and over the last 3 years Brooke sold SGTX stock worth over $0.
Brooke has made over 2 trades of the Sigilon Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Brooke exercised 2,680 units of SGTX stock worth $60,220 on 15 June 2024.
The largest trade Brooke's ever made was exercising 2,680 units of Sigilon Therapeutics stock on 15 June 2024 worth over $60,220. On average, Brooke trades about 734 units every 46 days since 2021. As of 15 June 2024 Brooke still owns at least 4,060 units of Sigilon Therapeutics stock.
You can see the complete history of Brooke Story stock trades at the bottom of the page.
Brooke's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W26LG.
Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui... és John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics executives and other stock owners filed with the SEC include: